Werewolf Therapeutics, Inc. (HOWL) Tops Q4 EPS by 16c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. QQQ
8. LDOS
9. HUM
10. CSCO

Go back to Werewolf Therapeutics, Inc. (HOWL) Tops Q4 EPS by 16c

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 23, 2023 7:00 AM EDT

Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumors 

Dosed first patient in Phase 1 clinical trial evaluating IL-12 INDUKINE WTX-330 in patients with advanced or metastatic solid tumors or lymphoma 

Nominated WTX-712, a conditionally active IL-21 INDUKINE molecule targeting oncology indications; preclinical data to be presented at AACR Annual Meeting 2023 in Orlando, Florida 

Updated cash runway guidance to fund cash flow requirements through at least 4Q 2024 

WATERTOWN, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Werewolf... More